cvs caremark glp-1 lawsuit to cover Zepbound again after lawsuit, widespread backlash CVS Caremark drops Zepbound coverage

confirm all-in $149 price includes medication before first charge FDA regulatory status (as of June 2026): FDA formally proposed on April 30, 2026 removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulks list (Federal Register notice published May 1, 2026: 91 Fed

Probiotics are generally safe to take alongside GLP-1 medications and may ease diarrhea

From MASH to Parkinson's disease, there is potential for GLP-1s to become a magic bullet' across healthcare, only adding to the ever-increasing market value

Future preclinical work may probe combinations with incretin-based agents or -oxidation enhancers to define mechanistic complementarity